Biomemory
FranceEntry
2024
Hold
2yr
Status
Active
Who owns Biomemory?
Biomemory is a French Biotech company, currently owned by Audacia since 2025 and 3 other investors.
Hand-verified · updated 2026-04-21
Open JSON · CC-BY
Most recent investor
Aloe Private EquitySorbonne Venture · 2022 · VC
4 ownership periods · full history below
Key facts
HQFrance
SectorBiotech
Key takeaways
- ·Co-held by Crédit Mutuel Equity, Crédit Mutuel Innovation, Aloe Private Equity and Audacia since 2024.
- ·4 distinct PE sponsors across ownership cycles.
Ownership history
4 ownership periods · co-invest detected
Active
Co-held by Crédit Mutuel Equity, Crédit Mutuel Innovation, Aloe Private Equity and Audacia since 2024.
Co-invest · 4 holders · 2024 · present
Crédit Mutuel EquityActive
2024 · present(2yr) · Crédit Mutuel Equity · 1992 · Growth
Aloe Private EquityActive
2024 · present(2yr) · Sorbonne Venture · 2022 · VC
Crédit Mutuel InnovationActive
2024 · present(2yr) · Crédit Mutuel Innovation Evergreen Capital · 2004 · Evergreen
AudaciaActive
2025 · present(1yr) · Sorbonne Venture by Audacia · 2020 · VC
More from Sorbonne Venture
Other portfolio companies in the same fund.
More PE-backed in TMT
Comparable tmt deals from other GPs.
US
Norway
Questions
Who owns Biomemory?
Biomemory is currently owned by Audacia, Crédit Mutuel Equity and 2 others, through Sorbonne Venture, since 2025.
When did Audacia and 3 others acquire Biomemory?
Audacia and 3 others acquired Biomemory in 2025.
Who has owned Biomemory over time?
Biomemory has been through 4 private-equity ownership periods: Crédit Mutuel Equity · via Crédit Mutuel Equity · since 2024; Crédit Mutuel Innovation · via Crédit Mutuel Innovation Evergreen Capital · since 2024; Aloe Private Equity · via Sorbonne Venture · since 2024; Audacia · via Sorbonne Venture by Audacia · since 2025.
Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue